Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 9Terminated 3Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 52Recurrence 6Neoplasms, Plasma Cell 5Neoplasms 3Immunoglobulin Light-chain Amyloidosis 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Paraproteinemias 2Lymphoma, Mantle-Cell 2Lymphoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Rhabdoid Tumor 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphadenopathy 1Leukemia, Myeloid, Acute 1Leukemia 1HIV Infections 1

Interventions

Rituximab 16Cyclophosphamide 16Prednisone 7Doxorubicin 7pirtobrutinib 6fludarabine 6Vincristine 6Lenalidomide 6venetoclax 5pembrolizumab 5fludarabine phosphate 5Etoposide 5Bendamustine Hydrochloride 5ibrutinib 4acalabrutinib 4Specimen Handling 4Magnetic Resonance Spectroscopy 4Dexamethasone 4CT-P10 4polatuzumab vedotin 3etoposide phosphate 3Immunotherapy, Adoptive 3tazemetostat 2liposomal doxorubicin 2Nivolumab 2Injections 2Ifosfamide 2Gemcitabine 2Cisplatin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, B-Cell × Bortezomib × Clear all
NCT01695941 2026-04-13

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡